Skip to main content

Table 6 Clinical characteristics of patients who developed an infection during immunosuppressive treatment

From: Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

  No. (%)
Clinical characteristics Infection
n = 29
No infection
n = 50
P
Cancer stagea    0.386
 Stage III 4 (14) 12 (24)  
 Stage IV 24 (86) 37 (76)  
Malignancy type    0.752
 Melanoma 19 (66) 36 (72)  
 Solid tumor 10 (34) 13 (26)  
 Hematologic 0 (0) 1 (2)  
Immune checkpoint inhibitor type    0.758
 Anti-CTLA-4 25 (86) 41 (82)  
 Anti-PD-1/L1 4 (14) 9 (18)  
Treatment for diarrhea or colitis    0.483
 Steroids alone 18 (62) 26 (52)  
 Steroids + infliximab 11 (38) 24 (48)  
Mean length of steroid use (days, SD) 80.4 (116) 46.7 (34.5) 0.063
Length of steroid use    0.160
 Short duration (≤ 30 days) 8 (28) 22 (44)  
 Long duration (> 30 days) 21 (72) 28 (56)  
Diarrhea grade    0.353
 Grade 1 3 (10) 10 (20)  
 Grade 2–4 26 (90) 40 (80)  
Colitis grade    1.000
 Grade 1 11 (38) 19 (38)  
 Grade 2–3 18 (62) 31 (62)  
  1. Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein-4; PD-1/L1, Programmed death-1/ligand 1; SD, standard deviation
  2. aStage of cancer was documented in 28 patients with infection and 49 patients with no infection